A New Parkinson’s Disease Drug Function in Inherited form of Parkinson’s Disease Breakthrough Discovery Offers Hope for Precision Therapy in Mitochondrial Dysfunction Disorders
Malvern, PA, Progenra Inc — June 16th, 2025 — Parkinson’s disease is the second most prevalent neurodegenerative disease and presents a global health challenge, effecting 10 million people world-wide. About 90,000 people are diagnosed with Parkinson’s disease in US every year. About 1.2 million people will suffer from Parkinson’s disease in US by year 2030, […]
Progenra Scientists Develop Technology to Discover Targeted Protein Degradation Drugs, PROTACs and Molecular Glues
Malvern, PA — Progenra, Inc. a biotech company focused neurodegenerative drugs is pleased to announce the development of a new technology that will facilitate rapid discovery of drugs that work via Targeted Protein Degradation (TPD). A wave new drug candidate, called PROTACs or molecular glue drugs are emerging from pharmaceutical and biotech companies that work […]